A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency

HIV Medicine

Volumn 5, Issue 3, 2004, Pages 140-143

  Chetchotisakd, Ploenchan ^a   Sungkanuparph, S ^b   Thinkhamrop, B ^c   Mootsikapun, P ^a   Boonyaprawit, P ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

Author keywords

Cryptococcal meningitis; Fluconazole; Fungal infection; Primary cryptococcal prophylaxis; Survival

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; FLUCONAZOLE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FUNGAL MENINGITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; T LYMPHOCYTE; THAILAND;

ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; FLUCONAZOLE; HUMANS; MALE; MENINGITIS, CRYPTOCOCCAL; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 2942630776     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00201.x     Document Type: Article

References (8)

1. Chariyalertsak S, Sirisanthana T, Saenwonloey O, Nelson KE. Clinical presentation and risk behaviors of patients with acquired immunodeficiency syndrome in Thailand, 1994-98: regional variation and temporal trends. Clin Infect Dis 2001; 32: 955-962.
2. Powdery WG. Cryptococcal meningitis and AIDS. Clin Infect Dis 1993; 17: 837-842.
3. Kaplan JE, Masur H, Holmes KK. Guidelines for the Prevention of Opportunistic Infections Among HIV-Infected Person 2002: Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51: 1-52.
4. Scharfstein J, Paltiel D, Freedberg K. The cost-effectiveness of fluconazole prophylaxis against primary systemic fungal infection in AIDS. Clin Infect Dis 1997; 17: 373-381.
5. Havlir DV, Dube MP, McCutchan A et al. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis 1998; 27: 1369-1375.
6. Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson KE. A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. Clin Infect Dis 2002; 24: 277-284.
7. Powerdy W, Finkelstein D, Feinberg J et al. A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced immunodeficiency virus infection. N Engl J Med 1995; 332: 700-705.
8. McKinsey DS, Wheat LJ, Cloud GA et al. Itraconazole prophylaxis for fungal infections in patients with advanced human immunodeficiency virus infection: randomized, placebo-controlled, double-blind study. Clin Infect Dis 1999; 28: 1049-1056.